Genelux (GNLX) Treasury Shares (2022 - 2026)

Genelux (GNLX) posted quarterly Treasury Shares of $433000.0 for Q1 2026, little changed quarter-over-quarter from $433000.0 in Q4 2025.

Genelux (GNLX) Treasury Shares (2022 - 2026) Analysis & Trends

Genelux's Treasury Shares history runs 5 years deep, the most recent figure standing at $433000.0 for Q1 2026.

In Q1 2026, Treasury Shares changed N/A year-over-year to $433000.0; the TTM figure through Mar 2026 stood at $433000.0 (changed N/A YoY), while the FY2025 annual figure was $433000.0, changed 0.0% from the prior year.
Treasury Shares for Q1 2026 stood at $433000.0, roughly flat from $433000.0 in the prior quarter.
The five-year high for Treasury Shares was $1.2 million in Q3 2025, with the low at -$433333.0 in Q4 2022.
The 5-year median for Treasury Shares is $0.0 (2022), against an average of $123113.1.
Peak annual rise in Treasury Shares reached 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
Genelux's Treasury Shares stood at $433000.0 in 2022, then changed by 0.0% to $433000.0 in 2023, then changed by 0.0% to $433000.0 in 2024, then changed by 0.0% to $433000.0 in 2025, then changed by 0.0% to $433000.0 in 2026.
Business Quant data shows GNLX's Treasury Shares at $433000.0 in Q1 2026, $433000.0 in Q4 2025, and $433000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Genelux	119.87 Mn	119.87 Mn	-	-433,333.00

Download Data